Elizabeth E. Reed - Sep 22, 2025 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Signature
/s/ Elizabeth E. Reed
Stock symbol
TVTX
Transactions as of
Sep 22, 2025
Transactions value $
-$59,200
Form type
4
Date filed
9/24/2025, 04:05 PM
Previous filing
May 5, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
REED ELIZABETH E Chief Legal Officer and GC C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DR., SUITE 300, SAN DIEGO /s/ Elizabeth E. Reed 2025-09-24 0001283303

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TVTX Common Stock Options Exercise $191K +10K +11.13% $19.08 99.9K Sep 22, 2025 Direct F1
transaction TVTX Common Stock Sale -$250K -10K -10.01% $25.00 89.9K Sep 22, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TVTX Employee stock option (right to buy) Options Exercise $0 -10K -20% $0.00 40K Sep 22, 2025 Common Stock 10K $19.08 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 396 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 31, 2025.
F2 This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 4, 2017 with an expiration date of January 4, 2027.
F3 The stock option is fully vested and exercisable.